The list of Triangle biotech and pharmaceutical development firms seeking to go public is getting longer.

The latest is Regado Biosciences.

The company, which is seeking to commercialize technology developed at Duke University, has filed for an initial public offering of stock.

Regado, which has raised more than $110 million in financing dating back to 2005, is seeking $75 million, according to the filing.

If the IPO is executed, Regado would trade on the Nasdaq under the symbol RGDO.

Cowen and Company, BMO Capital Markets, Canaccord Genuity, Needham & Company and Wedbush PacGrow Life Sciences are working with Regado as underwriters.

Funds will be used to develop one treatment in a Phase 3 clinical trial called REG1.

“We intend to use the net proceeds from this offering to fund further clinical development of REG1 and for working capital and other general corporate purposes,” Regado said in the filing. 

REG1 targets blood clotting and would be used in coronary intervention. REG1 could be used in open heart surgery.

Regado is developing technology from Duke University.

Regado’s DNA-based system could present an alternative to such drugs as Heparin and Coumadin, which help prevent heart attacks, strokes and deep-vein thrombosis but also increase the risk of uncontrolled bleeding.

Two other regional firms already have gone public this year, LipoScience and Chimerix.

Life science services firm Quintiles is also in the process of an IPO.

ChannelAdvisor, an ecommerce firm, also has filed papers to go public, 

Regado raised $51 million in new financing, including backing from Triangle-based Aurora Funds, on December. The company closed on a “D” round of financing totaling just over $21.5 million in July of 2011. Regado has been raising the latest funding since December 2009.

Regado is based in New Jersey but maintains its research and development lab in Durham.

The firm landed a new investor in December, RusnanoMedInvest, which is part of a Russian government-owned investment firm called Rusnano.

Other investors included Baxter Ventures, which also is a new investor, along with previous backers Edmond de Rothschild Investment Partners, Domain Associates, Quaker Partners, Aurora and Caxton Advantage Life Sciences Fund.

“We are proud to say this financing is among the largest private rounds to be completed in 2012,” said David J. Mazzo, Regado’s chief executive officer.

Regado raised $23 million in 2007 and $20 million in 2005.